Doxercalciferol interactions
Full monograph for DoxercalciferolCheck it against another medicine
Medicines
69 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Alendronic Acid + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Algae Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Major | Absorption · Synergy | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms | 7 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Major | Absorption · Synergy | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms | 7 sources — open the full entry |
| Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium + Vitamin D3 + Multimineral | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Citrate + Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multiminerals | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Phosphate [Milk source] + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Cholecalciferol [Vitamin D3] | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Conventional Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Coral Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Eggshell Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Eggshell Calcium + Vitamin D3 + 19 Vitamin & Minerals | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Ibandronic Acid + Algae Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Ibandronic Acid + Coral Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Paricalcitol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Sucralfate | Major | Absorption | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in… | 3 sources — open the full entry |
| Vitamin C + Vitamin D3 + Folic acid | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Calcium acetate + Magnesium carbonate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Digoxin | Moderate | Synergy | Excessive dosing of vitamin D can induce hypercalcemia, which may increase the risk of digitalis toxicity and serious arrhythmias due to additive inotropic… | 6 sources — open the full entry |
| Fosphenytoin Sodium | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Indapamide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Indapamide + Amlodipine | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Irbesartan + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Iron Sucrose | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Metabolism | Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4. The proposed… | 4 sources — open the full entry |
| Lefamulin Acetate | Moderate | Metabolism | When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with… | 6 sources — open the full entry |
| Lorlatinib | Moderate | Metabolism | Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is… | 3 sources — open the full entry |
| Losartan Potassium + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Magnesium Hydroxide | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Magnesium Hydroxide + Liquid Paraffin | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Magnesium Oxide | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Magnesium Sulfate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Mavacamten | Moderate | Metabolism | Coadministration with mavacamten may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, 2C9, and/or 2C19. The proposed… | 1 sources — open the full entry |
| Metolazone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Nebivolol + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Olmesartan Medoxomil + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
Conditions
Conditions in which Doxercalciferol needs care, as documented in this source.
Hypercalcemia
MajorVitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
4 sources
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
- "Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc (2002):
- "Product Information. Drisdol (ergocalciferol)." sanofi-aventis (2016):
Liver Diseases
ModerateVitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.
3 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
Therapeutic duplication
Drug classes that overlap with Doxercalciferol, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Os-cal extra d3
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Ortho df
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Alendronate/cholecalciferol